Ilex Medical publishes results for the third quarter of 2021, according to which net revenues in the quarter increased by approximately 4% and amounted to approximately NIS 310 million, compared with approximately NIS 297.5 million last year. In dollar terms, growth was recorded at 10%.
Gross profit for the quarter increased by approximately 54% and amounted to approximately NIS 141.6 million, compared with approximately NIS 91.8 million in the corresponding quarter last year. The gross profit margin was 45.7% compared to 30.9% in the corresponding quarter in 2020.
Operating profit for the quarter increased by approximately 76% and amounted to approximately NIS 106.9 million, compared with approximately NIS 60.6 million in the previous year.
EBITDA in the quarter increased by approximately 72% and amounted to approximately NIS 118.1 million, compared with approximately NIS 68.6 million last year.
The net profit attributed to the company’s shareholders in the quarter increased by approximately 69% and amounted to approximately NIS 84 million, compared with approximately NIS 49.6 million in the corresponding quarter in 2020.
Tami Galili, CEO of Ilex Medical: “The Corona epidemic accelerated the company’s growth and at the same time allowed us to develop new growth engines in the field of medical equipment, compete in the box office auctions and invest in innovative start-up companies. We continue to present record results with an excellent quarter indicating growth in all parameters. This quarter was affected by the fourth wave of the Corona epidemic, in which Ilex responded to the epidemic in a number of areas, including the Laboratory in Airport City. The results for the quarter reflect streamlining processes carried out in the laboratory that led to an improvement in profitability. The activity in the field of medical equipment back to levels represents the company, pre-Corona, and also there we show an improvement in profitability. As part of the strategy to build new growth engines, we announced an investment agreement with Starget Pharma. Under the agreement, Ilex will acquire up to 33% of the company, which specializes in cancer diagnosis and treatment, for a maximum of $ 10 million. “